CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 13,475 enrolled
Drug / intervention
selenium +3 moredrug
Likely dose
selenium 200 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00784225
NCT00784225Phase 3Completed
CompareCT.gov

S0000B: Prevention of Cataract and Age-Related Macular Degeneration With Vitamin E and Selenium - SELECT Eye Endpoints (SEE)

SWOG Cancer Research Network·interventional·Posted Nov 3, 2008·Updated Aug 14, 2019

In Brief

A Phase 3 clinical trial evaluating selenium, vitamin E, and 2 other interventions for Cataract and Macular Degeneration. Completed, enrolled 13,475 participants across 1 site.

Detailed Summary

RATIONALE: Aging may affect a person's vision. Vitamin E and/or selenium may help prevent cataracts or age-related macular degeneration in men receiving these drugs as part of a clinical trial for the prevention of prostate cancer. PURPOSE: This clinical trial is studying vitamin E and/or selenium to see how well they work in preventing cataract and age-related macular degeneration in men enrolled on SELECT (SWOG-S0000).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCataract, Macular Degeneration
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI), National Eye Institute (NEI)

Timeline

Phase 3CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 3, 2008
Enrollment StartJul 1, 2004
Primary CompletionNov 1, 2017
Study CompletionMay 1, 2018
TodayJul 2, 2026
Enrollment to primary: 13.3 yearsPosted 17.7 years ago

Interventions

seleniumdrug

200 mcg daily for 7-12 years

vitamin Edrug

400 IU daily by mouth for 7-12 years

vitamin E placebodrug

daily for 7-12 years

selenium placebodrug

daily for 7-12 years